Natalie Jäger

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.

This study identifies cell-state plasticity as a driver of heterogeneity in Group 3/4 medulloblastomas, showing that transcription factor perturbation can redirect tumor cells along different differentiation trajectories.

The paper identifies four immune clusters in pediatric nervous system tumors using RNA-seq data and validates them with multiple methods, highlighting the need for personalized immunogenomic profiling.

This study benchmarks somatic mutation calling in cancer genomes, identifying inconsistencies and proposing solutions to improve accuracy.

This study compares whole genome sequencing pipelines across five centers using a uniform tumor-normal sample pair, identifying factors affecting output consistency.